Ardent Health (NYSE:ARDT) Stock Rating Lowered by Wall Street Zen

Ardent Health (NYSE:ARDT) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday.

A number of other brokerages have also weighed in on ARDT. Guggenheim lowered their price objective on shares of Ardent Health from $18.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Truist Financial decreased their target price on shares of Ardent Health from $21.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 14th. UBS Group initiated coverage on shares of Ardent Health in a research report on Wednesday, September 10th. They set a “buy” rating and a $17.00 price target for the company. KeyCorp cut Ardent Health from an “overweight” rating to a “sector weight” rating in a research note on Monday, November 17th. Finally, Mizuho decreased their price objective on Ardent Health from $20.00 to $13.00 and set an “outperform” rating on the stock in a report on Tuesday, November 18th. Six research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.00.

Ardent Health Price Performance

ARDT opened at $8.93 on Friday. The stock has a 50-day moving average price of $13.26 and a 200-day moving average price of $13.15. Ardent Health has a 12-month low of $8.28 and a 12-month high of $17.34. The company has a current ratio of 2.08, a quick ratio of 1.95 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $1.28 billion, a P/E ratio of 6.16, a PEG ratio of 7.34 and a beta of 0.44.

Ardent Health (NYSE:ARDT) last announced its quarterly earnings data on Wednesday, November 12th. The company reported $0.52 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.10. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.55 billion. Ardent Health had a return on equity of 19.02% and a net margin of 3.24%. Ardent Health has set its FY 2025 guidance at 0.850-1.030 EPS. Equities analysts predict that Ardent Health will post 1.23 earnings per share for the current fiscal year.

Institutional Trading of Ardent Health

Several large investors have recently modified their holdings of ARDT. Oliver Luxxe Assets LLC raised its position in Ardent Health by 1.5% during the 2nd quarter. Oliver Luxxe Assets LLC now owns 87,639 shares of the company’s stock valued at $1,197,000 after purchasing an additional 1,319 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Ardent Health by 0.6% during the second quarter. Geode Capital Management LLC now owns 286,848 shares of the company’s stock valued at $3,918,000 after buying an additional 1,769 shares during the period. CWM LLC raised its holdings in shares of Ardent Health by 990.6% during the second quarter. CWM LLC now owns 2,203 shares of the company’s stock valued at $30,000 after acquiring an additional 2,001 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Ardent Health by 8.3% in the second quarter. The Manufacturers Life Insurance Company now owns 27,530 shares of the company’s stock worth $376,000 after acquiring an additional 2,110 shares during the period. Finally, Strs Ohio lifted its stake in Ardent Health by 6.3% in the third quarter. Strs Ohio now owns 42,400 shares of the company’s stock worth $562,000 after acquiring an additional 2,500 shares during the period.

About Ardent Health

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.